New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2014
05:49 EDTBSXBoston Scientific presents data on Precision Spectra SCS
New retrospective data highlighting the Boston Scientific Precision Spectra Spinal Cord Stimulator, or SCS, System demonstrate the device provided sustained and highly significant relief of low-back pain six months after implantation. The retrospective study of 213 patients at 13 centers is focused on patients with chronic pain who were treated with the Precision Spectra SCS System. To date, 140 patients have reached six months post-implant. Results include: Sustained and highly significant reduction in pain from an average baseline score of 7.15, on a 10-point scale, to an average score of 2.93 at six months post-implant. In those patients with only low-back pain, sustained and highly significant reduction of low back pain, from an average baseline score of 7.53, on a 10-point scale, to an average of 3.45 at six months post-implant. In those patients with severe low back pain, sustained and highly significant reduction in pain, from an average score of 8.78 at baseline to 3.68 at 6 months post-implant.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
16:17 EDTBSXNevro submits preliminary response to PTAB in patent case with Boston Scientific
Nevro (NVRO) announced that the company has submitted its preliminary response to the Patent Trial and Appeals Board, or PTAB, in response to two petitions for inter partes review, or IPR, filed by a unit of Boston Scientific (BSX), challenging the validity of certain claims in U.S. Patent No. 8,359,102, one of Nevro's 55 issued U.S. patents directed to Nevro's innovations in the neuromodulation field. The preliminary response is limited in scope by the rules governing the IPR process. The response is limited to setting forth the reasons why an IPR should not be instituted and cannot argue the merits or include any new testimonial evidence. By the rules governing the IPR process, the next step will be a decision by the PTAB to either institute or deny review of the petition. That determination is expected by December 1, Nevro said.
August 27, 2015
10:00 EDTBSXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:12 EDTBSXBoston Scientific upgraded to Buy on valuation at Goldman
Subscribe for More Information
August 24, 2015
16:32 EDTBSXBoston Scientific announces CE Mark for MRI labeling for ICD, CRT-D systems
Boston Scientific has received CE Mark on magnetic resonance imaging conditional labeling for the current family of EL and MINI implantable cardioverter defibrillator and the X4 cardiac resynchronization therapy defibrillator systems. This revised labeling ensures that future patients and those already implanted with these systems are able to undergo MRI scans if indicated.
August 19, 2015
16:48 EDTBSXBoston Scientific announces FDA approval of Innova Self-Expanding Stent System
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use